SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------------------------
FORM 10-Q
Quarterly Report Under Section 13 or 15(d)
of the
Securities Act of 1934
FOR QUARTER ENDED SEPTEMBER 30, 2002
Commission File Number 0-12248
DAXOR CORPORATION
(Exact Name as Specified in its Charter)
New York 13-2682108
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)
350 Fifth Ave
Suite 7120
New York, New York 10118
(Address of Principal Executive Offices & Zip Code)
Registrant's Telephone Number: (212) 244-0555
(Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports
required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes |X| No |_|
Indicate the number of shares outstanding of each of the issuer's classes
of common stock, as of the latest practicable date.
CLASS OUTSTANDING AT SEPTEMBER 30,2002
- --------------------------------------------------------------------------------
COMMON STOCK
PAR VALUE: $.O1 per share 4,662,909
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS PAGE
----
Consolidated Balance Sheet as at September 30, 2002 and
December 31, 2001 F-1
Consolidated Statements of Income (Unaudited) for the
Three and Nine Months ended September 30,2002 and 2001 F-2
Consolidated Statements of Cash Flows (Unaudited) for the Nine
Months ended September 30, 2002 and 2001 F-3
Notes to Consolidated Financial Statements (Unaudited) F-4&5
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS: RESULTS OF OPERATIONS AND
FINANCIAL CONDITION
DAXOR CORPORATION
FINANCIAL STATEMENTS
================================================================================
DAXOR CORPORATION
CONSOLIDATED BALANCE SHEETS [UNAUDITED]
September 30, December 31,
2002 2001
---- ----
ASSETS
==================================================================================
CURRENT ASSETS
Cash $ 21,814 $ 431,949
Marketable Securities at Fair Value
September 30,2002 and December 31,
2001. (Notes 1 and 2) 37,551,238 42,271,902
Accounts receivable 174,590 174,242
Other current assets 318,313 312,310
------------ ------------
Total Current Assets 38,065,955 43,190,403
EQUIPMENT AND IMPROVEMENTS
Storage tanks 125,815 125,815
Leasehold improvements, furniture
and equipment 880,280 837,807
Laboratory equipment 290,104 288,087
------------ ------------
1,296,199 1,251,709
Less: Accumulated depreciation and amortization 1,016,084 975,593
------------ ------------
Net equipment and improvements 280,115 276,116
Other Assets 72,184 73,634
Total Assets $ 38,418,254 $ 43,540,153
------------ ------------
- ----------------------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY
==================================================================================
CURRENT LIABILITIES
Accounts payable and accrued liabilities $ 53,100 $ 52,855
Loans payable (Notes 1 and 2) 909,792 1,000,000
Other Liabilities 90,194 22,885
Deferred Taxes (Note 1) 5,339,170 7,135,446
------------ ------------
Total Liabilities 6,392,256 8,211,186
SHAREHOLDERS' EQUITY
Common stock, par value $.01 per share:
Authorized 10,000,000 shares: issued and
outstanding shares 4,662,909 September 30,
2002 and 4,664,909 December 31, 2001 53,097 53,097
Additional Paid in capital 9,798,232 9,798,232
Net unrealized holding gains
on available-for-sale securities (Note 1) 10,364,271 13,851,161
Retained earnings 16,655,681 16,440,007
Treasury stock (4,845,283) (4,813,530)
------------ ------------
Total Shareholders' Equity 32,025,998 35,328,967
Total Liabilities and Shareholders' Equity $ 38,418,254 $ 43,540,153
============ ============
See accompanying notes to cosolidated financial statements
F-1
DAXOR CORPORATION
CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
THREE MONTHS ENDED NINE MONTHS ENDED
September 30, September 30,
2002 2001 2002 2001
---- ---- ---- ----
REVENUES:
- -----------------------------------------------------------------------------------------------
Operating revenues $ 200,100 $ 185,705 $ 589,604 $ 464,699
Other revenues 6,522 44,180 28,337 143,504
Dividend income 507,454 452,536 1,415,997 1,391,701
Gains (losses) on sale
of securities 80,194 2,171 175,258 11,902
Total Revenues 794,270 684,592 2,209,196 2,011,806
----------- ----------- ---------- ----------
- -----------------------------------------------------------------------------------------------
COSTS AND EXPENSES
- -----------------------------------------------------------------------------------------------
Operations of Laboratories 172,244 171,577 575,028 600,790
Selling, General, and
Administrative 510,251 344,594 1,378,022 1,015,196
Interest expense, net of
interest income 7,475 32,320 26,268 101,903
----------- ----------- ---------- ----------
Total Costs and Expenses 689,970 548,491 1,979,318 1,717,889
----------- ----------- ---------- ----------
Net Income (Loss) Before Income
Taxes 104,300 136,101 229,878 293,917
Provision for income taxes (709) (2,864) 14,204 20,728
----------- ----------- ---------- ----------
Net Income (Loss) $ 105,009 $ 138,965 $ 215,674 $ 273,189
=========== =========== ========== ==========
Weighted Average Number of
Shares Outstanding 4,663,909 4,664,909 4,664,576 4,664,909
Net Income or (Loss) per Common
Equivalent Share $ 0.03 $ 0.03 $ 0.05 $ 0.06
=========== =========== ========== ==========
See accompanying notes to financial statements
F-2
DAXOR CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
FOR THE NINE MONTHS ENDED
SEPTEMBER 30, SEPTEMBER 30,
2002 2001
---- ----
CASH FLOWS FROM OPERATING ACTIVITIES
Net income or (loss) $ 215,674 $ 273,189
--------------------------------
Adjustments to reconcile net income
(loss) to net cash provided by
operating activities:
Depreciation and Amortization 42,241 34,801
(Gain) loss on sale of investments (175,258) (11,902)
Change in assets and liabilities:
(Increase) decrease in accounts receivable (348) (78,022)
(Increase) decrease in other current assets (6,003) (19,425)
(Increase) decrease in other assets net of amortization (300) 1,100
Increase (decrease) in accounts payable, accrued
and other liabilities net of "short sales" 1,248 (3,784)
--------------------------------
Total adjustments (138,420) (77,232)
--------------------------------
--------------------------------
Net cash provided by or (used in) operating activities 77,254 195,957
CASH FLOWS FROM INVESTING ACTIVITIES:
Payment for purchase of equipment and
improvements (44,490) (994)
Net cash provided or (used) in purchase
and sale of investments (403,372) (354,404)
Net proceeds (repayments) of loans from
brokers used to purchase investments 209,792 192,918
Proceeds from "short sales" not closed 82,434 3,609
--------------------------------
Net cash provided by or (used in) investing activities (155,636) (158,871)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of bank loan (300,000) 0
Payment for purchase of treasury stock (31,753) 0
Net cash provided by or (used in) financing activities (331,753) 0
---------
Net increase (decrease) in cash and cash
equivalents (410,135) 37,086
Cash and cash equivalents at beginning of year 431,949 18,439
--------------------------------
Cash and cash equivalents at end of period $ 21,814 $ 55,525
================================
See accompanying notes to financial statements
F-3
DAXOR CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
NINE MONTHS ENDED SEPTEMBER 30, 2002 AND 2001
In the opinion of the Company, the accompanying unaudited consolidated
financial statements contain all adjustments (consisting of only normal
recurring accruals) necessary to present fairly the financial position as of
September 30,2002, and December 31, 2001, the results of operations for the
three and nine months ended September 30,2002 and 2001 and cash flows for the
nine months ended September 30, 2002 and 2001. The consolidated financial
statements include the accounts of the Company and its subsidiary. All
significant intercompany transactions and balances have been eliminated in
consolidation.
(1) MARKETABLE SECURITIES
Upon adoption of FASB No. 115, management has determined that the
company's portfolio is best characterized as "Available-For-Sale". This has
resulted in the balance sheet carrying value of the company's marketable
securities investments, as of September 30, 2002 and December 31, 2001 being
increased approximately 71.88% and 98.60% respectively over its historical cost.
A corresponding increase in shareholders' equity has been effectuated. In
accordance with the provisions of FASB No. 115, the adjustment in shareholders'
equity to reflect the company's unrealized gains has been made net of the tax
effect had these gains been realized.
The following tables summarize the company's investments as of :
September 30, 2002
------------------
Unrealized Unrealized
Type of security Cost Fair Value holding gains holding losses
- ---------------- ---- ---------- ------------- --------------
Equity $21,817,128 $37,537,738 $17,336,476 $1,615,866
Debt 30,669 13,500 -0- 17,169
----------- ----------- ----------- ----------
Total $21,847,797 $37,551,238 $17,336,476 $1,633,035
=========== =========== =========== ==========
December 31, 2001
-----------------
Unrealized Unrealized
Type of security Cost Fair Value holding gains holding losses
- ---------------- ---- ---------- ------------- --------------
Equity $21,270,436 $42,271,002 $21,182,144 $181,578
Debt 14,859 900 0 13,959
Total $21,285,295 $42,271,902 $21,182,144 $195,537
=========== =========== =========== ========
At September 30, 2002 the securities held by the Company had a market
value of $ 37,551,238 and a cost basis of $ 21,847,797 resulting in a net
unrealized gain of $ 15,703,441 or 71.88% of cost.
At December 31, 2001 the securities held by the Company had a market value
of $42,271,902 and a cost basis of $ 21,285,295 resulting in a net unrealized
gain of $20,986,607 or 98.60% of cost.
At September 30, 2002 and December 31, 2001 marketable securities,
primarily consisting of preferred and common stocks of utility companies, are
valued at fair value.
(2) LOANS PAYABLE
As at September 30, 2002 and December 31, 2001, the Company had loans
outstanding aggregating $700,000 and $1,000,000 borrowed on a short term basis
from a bank, which are secured by certain marketable securities of the Company.
The loans bear interest at approximately 4.2%.
Short term margin debt due to brokers secured by the Companies marketable
securities, totaled $209,792 at September 30, 2002 and $-0- at December 31,
2001.
Part II OTHER INFORMATION
Item 1.
Legal Proceedings
None
MANAGEMENT'S DISCUSSION AND ANALYSIS
RESULTS OF OPERATIONS AND FINANCIAL CONDITION
ITEM 2.
RESULTS OF OPERATIONS
Three months ended September 30, 2002 as compared with three months ended
September 30, 2001.
For the three months ended September 30, 2002 total revenues were $794,270
up from $684,592 in 2001. Operating revenues were $200,100 in 2002 up from
$185,705 in 2001. Dividend income was $507,454 with a net interest expense of
$7,475 in 2002, as compared to dividend income of $452,536 with a net interest
expense of $32,320 in 2001. In 2002, the Company had a net income before income
taxes, of $104,300 versus a net income before income taxes of $136,101 in 2001.
The Company anticipates that it's sales of equipment and kits will become the
major source of income for the Company.
Nine months ended September 30, 2002 as compared with nine months ended
September 30, 2001.
For the nine months ended September 30,2002, total revenues were
$2,209,196 up from $2,011,806 in 2001. Operating revenues were $589,604 up from
$464,699 in 2001. Dividend income was $1,415,997 with a net interest expense of
$26,268, as compared to the dividend income of $1,391,701 with a net interest
expense of $101,903 in 2001. In 2002, the Company had $175,258 in capital gains
vs. $11,902 in 2001. In 2002, the Company had a net income before income taxes
of $229,878 versus $293,917 before income taxes in 2001. The Company has adopted
a policy that encourages leasing or renting of equipment to enable hospitals to
test the equipment. This results in a sale of kits but a slower recognition of
operating income from BVA sales. The increase in operating revenues was
primarily related to the increase in sales of the kits used in conjunction with
the Blood Volume Analyzer.
LIQUIDITY AND CAPITAL RESOURCES
At September 30, 2002 the Company had total assets of $38,418,254 and
total liabilities of $6,392,256 with shareholders' equity of $32,025,998. The
Company has a net pre-taxed unrealized gain of $15,703,441 and $10,364,271 of
net after tax unrealized capital gains on available-for-sale securities in its
portfolio. This amount is included in the calculation of Total Shareholders'
Equity. The Company's stock portfolio had a market value of $37,551,238 with
short-term loans of $909,792 with 4,662,909 shares outstanding.
The Company has adequate resources for the current marketing level of its
Blood Volume Analyzer as well as capital to sustain its localized semen and
blood banking services. In June 2002, the Company engaged in a search firm for
the development of a national sales force. In September, Richard Prall was hired
as Vice-President of sales. In addition, three regional sales managers for the
Mid-West, Northeast, and South central were also hired. These regional managers
previously worked with GE Medical Services and Toshiba Medical Services in the
area of Nuclear Medicine. This addition to the staff is part of the Company's
implementation of its previous announced plans to develop a nationwide sales
force. The new sales team will initially result in an increased cost to the
Company as they undergo intensive training in utilization of the Blood Volume
Analyzer. The
three regional sales managers had previously worked with Mr. Prall at various
times. This has shortened the development time for an integrated managerial
sales team. It is anticipated that two or three additional regional managers
will be named soon. It is the goal of the marketing team to develop an
individual sales team for each regional manager. The Company is also expanding
its support services personnel. The decision to develop the marketing team was
partially based on the anticipation of new publications in peer reviewed medical
journals by current users of the Blood Volume Analyzer. The Company's goal is to
establish blood volume measurement as a standard of care in multiple areas of
medicine and surgery. It is hoped that publication of research studies from
leading medical facilities will enable an increase in sales in both the Blood
Volume Analyzer and it's associated kits.
The Company has an instrument loaner reagent plan which requires use of the
Company's reserves. Under a sale or a lease plan, the Company receives income
immediately on its equipment. The equipment loaner reagent plan permits a user
to make a minimal initial capital commitment. This results in a slower return on
capital expenditure for the Company. The Company is currently leasing its
equipment directly. The Company is currently negotiating with an independent
leasing company to whom it will sell the BVA-100. Under these circumstances, a
sale would be immediately recognized by the Company. The Company is evaluating
blood volume instrumentation management programs for hospitals. Under such a
plan, the Company would provide equipment and personnel on a sub-contract basis.
The Company will use its current financial reserves primarily for developing and
marketing the Blood Volume Analyzer. The Company is evaluating various options
to expand blood banking services in conjunction with the use of the Blood Volume
Analyzer.
The Company did not file any reports on form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DAXOR CORPORATION
-----------------
(Registrant)
DATE: November 13,2002
- ---------------------- ------------------------------
JOSEPH FELDSCHUH, M.D.
President
DATE: November 13,2002
- ---------------------- ------------------------------
GARY FISCHMAN, Ph.D.
Vice President
DATE: November 13,2002
- ---------------------- ------------------------------
STEPHEN FELDSCHUH
Acting Treasurer
DATE: November 13,2002
- ---------------------- ------------------------------
DIANE MEEGAN
Corporate Secretary